-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ARFMfzAGfXNCsMyPLlmlE9bnTfSyo9j8zCbERFmroVEc1WZjzemIiucelF5goiWg 7j4zbq0AX+Zuyaf9aAYHFQ== 0001279569-08-001149.txt : 20081021 0001279569-08-001149.hdr.sgml : 20081021 20081021112947 ACCESSION NUMBER: 0001279569-08-001149 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20081021 FILED AS OF DATE: 20081021 DATE AS OF CHANGE: 20081021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BELLUS Health Inc. CENTRAL INDEX KEY: 0001259942 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50393 FILM NUMBER: 081132795 BUSINESS ADDRESS: STREET 1: 275 ARMAND-FRAPPIER BLVD. CITY: LAVAL STATE: A8 ZIP: H7V 4A7 BUSINESS PHONE: 450-680-4500 MAIL ADDRESS: STREET 1: 275 ARMAND-FRAPPIER BLVD. CITY: LAVAL STATE: A8 ZIP: H7V 4A7 FORMER COMPANY: FORMER CONFORMED NAME: NEUROCHEM INC DATE OF NAME CHANGE: 20030814 6-K 1 bellus6k.htm FORM 6-K bellus6k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Form 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the month of: October, 2008
 
Commission File Number: 000-50393
 
 
BELLUS Health Inc.
275 Armand-Frappier Boulevard
Laval, Québec
H7V 4A7
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F o
Form 40-F x
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Yes o
No x
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
 
Yes o
No x
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
 
Yes o
No x
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):__________
 
 
 
 
 
SIGNATURES:
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
  BELLUS Health Inc.  
       
Date: October 21, 2008
By:
/s/ David Skinner  
    Name: David Skinner  
    Title: Vice-President, General Counsel and Corporate Secretary  
       
 
EXHIBIT INDEX
 
Exhibit
   Description
     
99.1
   News Release dated October 21, 2008 - BELLUS Health provides update on activities
 
 EX-99.1 2 ex991.htm NEWS RELEASE DATED OCTOBER 21, 2008 ex991.htm 
Exhibit 99.1
News release via CNW Telbec, Montreal 514-878-2520

	    Attention Business/Financial Editors:
	    BELLUS Health provides update on activities

	    LAVAL, QC, Oct. 21 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS;
TSX: BLU) is pleased to provide an update on its branded nutraceutical and
pharmaceutical activities. The commercial activities surrounding sales of its
first natural health product, VIVIMIND(TM), to protect memory function are in
full gear. Through BELLUS Health's wholly owned subsidiary, OVOS Natural
Health Inc., VIVIMIND(TM) became available at the beginning of September on
the Internet and progressively at over 2,000 retail points of sale across
Canada. The distribution of the brand is on target as OVOS Natural Health has
received many orders from major national drug, grocery, and mass merchandisers
and Quebec natural health food stores, which will further translate into
VIVIMIND(TM) becoming increasingly available to consumers by year-end. The
Company is committed to the success of VIVIMIND(TM) and has therefore launched
extensive marketing, sales and public relations campaigns to increase
awareness and media exposure of the brand across Canada.
	    Targeted at healthy baby boomers, VIVIMIND(TM) is a patent-protected,
clinically tested, scientifically proven brand that is being offered to
consumers to protect their aging memory. VIVIMIND(TM)'s uniqueness and
efficacy are anticipated to not only take market share in the current
cognition brand segment, but also grow the size of the market. VIVIMIND(TM) is
expected to create and address a largely underserved self-care market. As part
of its commercial activities to grow and expand into the global market, OVOS
Natural Health is actively taking steps to launch in other geographies as
early as 2009 and 2010, via large retail organizations and via potential
partners with proven track records in the natural health, consumer health,
multi-level marketing and naturopathic doctor channels. Eight months into the
creation of OVOS Natural Health, the masthead brand VIVIMIND(TM) has reached
all milestones in its commercial launch development and is on track to deliver
its 2008 sales projections.
	    The pharmaceutical programs are also progressing; BELLUS Health is
advancing its programs in Type II diabetes and certain features of metabolic
syndrome and Alzheimer's disease. The Company expects to file the
Investigational New Drug application for the second Phase III clinical trial
for eprodisate (KIACTA(TM)) for the treatment of Amyloid A amyloidosis in the
fourth quarter of 2008.
	    With respect to this second Phase III KIACTA(TM) clinical trial, a new
protocol was developed that includes outcome measures that are similar to
those used in the first Phase II/III clinical trial but with greater focus on
renal disease. The new Phase III protocol was submitted for the Special
Protocol Assessment and for Protocol Assistance to the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency (EMEA), respectively.
The FDA has accepted that a p-value of less than 0.05 would be sufficient to
consider the second confirmatory trial for a New Drug Application. BELLUS
Health is pursuing its discussions with the FDA to finalize the study design
details. As well, discussions with the EMEA to conclude on the protocol are
progressing well and its finalization is expected in the coming months. The
Company has already identified more than 40 sites across the world for the
second Phase III clinical trial with close to 190 potentially eligible
patients.
	    The Company is also looking into various financing scenarios to take
place in the coming months. Picchio Pharma and its affiliates have expressed
their commitment to participate and to purchase at least 30% of the next
financing.

	    About BELLUS Health

	    BELLUS Health is a global health company focused on the development and
commercialization of products to provide innovative health solutions to
address critical unmet needs.

	    To Contact BELLUS Health

	    For additional information on BELLUS Health and its drug development
programs, please call the Canada and United States toll-free number
1 877 680 4500 or visit the Web Site at www.bellushealth.com.

	    Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond BELLUS Health
Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are
not limited to: the impact of general economic conditions, general conditions
in the pharmaceutical and/or nutraceutical industry, changes in the regulatory
environment in the jurisdictions in which the BELLUS Health Group does
business, stock market volatility, fluctuations in costs, and changes to the
competitive environment due to consolidation, that actual results may vary
once the final and quality-controlled verification of data and analyses has
been completed, as well as other risks disclosed in public filings of BELLUS
Health Inc. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance, if any, on any forward-looking statements
included in this news release. These statements speak only as of the date made
and BELLUS Health Inc. is under no obligation and disavows any intention to
update or revise such statements as a result of any event, circumstances or
otherwise, unless required by applicable legislation or regulation. Please see
the Annual Information Form of BELLUS Health Inc. for further risk factors
that might affect the BELLUS Health Group and its business.

	    %SEDAR: 00012022EF          %CIK: 0001259942

	    /For further information: Lise Hebert, Ph.D., Vice President, Corporate
Communications, (450) 680-4572, lhebert(at)bellushealth.com; Felicia Amilcar,
MBA, CFA, Director, Investor Relations, (450) 680-4572,
familcar(at)bellushealth.com/
	    (BLUS BLU.)

CO:  BELLUS Health Inc.

CNW 07:00e 21-OCT-08
-----END PRIVACY-ENHANCED MESSAGE-----